News | May 05, 2023
Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
Nous-209 has been developed using the Nouscom's viral vector platform
Nous-209 has been developed using the Nouscom's viral vector platform
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
Proposed combination enhances Pfizer’s position as a leading company in oncology
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Subscribe To Our Newsletter & Stay Updated
